The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Forest Laboratories's revenues will decrease -23.7% and EPS will contract -76.9%.
The average estimate for revenue is $805.0 million. On the bottom line, the average EPS estimate is $0.18.
Last quarter, Forest Laboratories chalked up revenue of $722.7 million. GAAP reported sales were 40% lower than the prior-year quarter's $1.20 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.21. GAAP EPS were -$0.58 for Q3 against $1.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 78.6%, 60 basis points better than the prior-year quarter. Operating margin was -26.6%, much worse than the prior-year quarter. Net margin was -21.4%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $3.09 billion. The average EPS estimate is $0.40.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Forest Laboratories is outperform, with an average price target of $37.45.
- Add Forest Laboratories to My Watchlist.